title: [Anticancer drugs under pressure].
abstract: Angiogenesis inhibitor drugs, targeting VEGF (vascular endothelial growth factor) are used increasingly in oncology for a wide range of advanced cancers (colorectal cancer, lung cancer, renal cell cancer,...). Generally, they are well tolerated but cardiovascular and renal side effects may appear. The most frequent complications are hypertension and proteinuria which, very often, remain asymptomatic. Therefore, they have to be searched for systematically before and during the treatment. Sometimes, anti-hypertensive medication is needed. We are just beginning to understand the pathophysiological mechanisms of antiangiogenic therapies. Only a multidisciplinary approach will improve our knowledge of those target agents and allow a better management of the cancer patient.
authors.affiliation: Service d'oncologie, HUG, 1211 Genève. assma.benaissa@hcuge.ch
authors.forename: A
authors.initials: A
authors.lastname: Ben Aïssa
authors.forename: A-C
authors.initials: AC
authors.lastname: George
authors.forename: F Z
authors.initials: FZ
authors.lastname: El M'Rabet
authors.forename: N
authors.initials: N
authors.lastname: Mach
authors.forename: P-Y
authors.initials: PY
authors.lastname: Dietrich
authors.forename: A
authors.initials: A
authors.lastname: Pechère-Bertschi
mesh_terms: D000419:Albuminuria / Q000139:chemically induced* / Q000503:physiopathology; D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy; D018570:Risk Assessment; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A